Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 1 od 46  
Back povratak na rezultate
2020, vol. 77, br. 8, str. 789-795
Korelacija između kvantifikacionih skorova metaboličkog sindroma i brojnih laboratorijskih parametara udruženih sa njim
aUniverzitet u Beogradu, Medicinski fakultet, KBC 'Bežanijska kosa'
bClinical Centre of Serbia, Clinic for Emergency Internal Medicine, Belgrade + Univerzitet u Beogradu, Medicinski fakultet
cUniverzitet u Beogradu, Medicinski fakultet, Institut za medicinsku statistiku i informatiku
dVojnomedicinska akademija, Klinika za očne bolesti, Beograd + Univerzitet odbrane, Medicinski fakultet Vojnomedicinske akademije, Beograd
eUniverzitet u Beogradu, Medicinski fakultet, KBC 'Zemun'
fKlinički centar Srbije, Centar za medicinsku biohemiju, Beograd
gUniverzitet u Beogradu, Medicinski fakultet, Univerzitetska dečija klinika
hUniverzitet u Beogradu, Medicinski fakultet + Klinički centar Srbije, Klinika za endokrinologiju dijabetes i bolesti metabolizma, Beograd
iUniverzitet u Beogradu, Medicinski fakultet + Vojnomedicinska akademija, Klinika za urgentnu internu medicinu, Beograd
jUniverzitet u Beogradu, Medicinski fakultet, KBC 'Bežanijska kosa' + Univerzitet u Beogradu, Medicinski fakultet

e-adresavesnadsendo@gmail.com
Sažetak
Uvod/Cilj. Metabolički sindrom (MS) karakterišu osnovni faktori rizika [obim struka (OS), poremećaji glikoregulacije, hipertenzija, hipertrigliceridemija, nizak HDL-holesterol] kao i pridruženi faktori rizika - insulinska rezistencija (IR), C-reaktivni protein (CRP), mokraćna kiselina, inhibitor aktivacije plazminogena-1 (PAI-1), fibrinogen, hiperhomocisteinemija (HHci), nealkoholna masna bolest jetre (NAMBJ) i mikroalbuminurija. Cilj rada bio je da se analiziraju osnovni i pridruženi faktori rizika od MS kod bolesnika sa i bez MS i ustanovi korelacija siMS skora i siMS skora rizika sa osnovnim i pridruženim faktorima rizika od MS. Metode. Studijom su bila obuhvaćena 148 bolesnika sa prekomernom telesnom težinom [body mass index ((BMI) 25-30 kg/m2) i gojazni (BMI > 30 kg/m2), starosti 30-75 godina, podeljeni u dve grupe: I - sa MS (68 bolesnika) i II - bez MS (80 bolesnika). Korišćeni su siMS skor, kao metod za kvantifikaciju MS, i siMS skor rizika, kao indikator aterosklerotskih komplikacija. Rezultati. Bolesnici sa MS imali su statistički značajno više vrednosti OS, hipertenzije, triglicerida (p < 0,001), glikemije (p = 0,006), kao i pridruženih faktora rizika od MS [HOMA IR (p = 0,002) CRP (p = 0,01) mokraćne kiseline (p < 0,001), alanin aminotranferaze (ALT) (p = 0,007) i gama-glutamil transferaze (GGT) (p = 0,001)] i niže vrednosti HDL-holesterol, (p < 0,001) u odnosu na bolesnika bez MS. Skor siMS pokazao je korelaciju sa pridruženim faktorima MS [log HOMA IR, logCRP, mokraćnom kiselinom (p < 0,001) i fibrinogenom (p = 0,005), parametrima jetrene funkcije: logALT (p = 0,001), log GGT, (p < 0,001) i bubrežne funkcije: kreatininom (p = 0,013) i serumskim proteinima (p = 0,006)]. Skor siMS rizika je statistički značajno korelirao sa vrednostima homocisteina, trombocita, mokraćne kiseline, uree, albumina i proteina. Zaključak. Statistički značajno više vrednosti pridruženih faktora rizika od MS (HOMA-R, CRP, mokraćne kiseline, ALT, GGT) kod bolesnika sa MS potvrđene su i korelacijom sa siMS skorom. Skor siMS ukazuje na to da su insulinska rezisencija, CRP, fibrinogen, mokraćna kiselina, NAMBJ pridruženi faktori rizika od MS. Skor siMS rizika ukazuje na to da gojaznost i hiperproteinski unos povećavaju HHCi sa starenjem, te da povećavaju rizik od bubrežnih poremećaja i aterosklerotskih komplikacija.
Reference
Abd, E.S.M., El-Den, A.E.M. (2015) Non-alcoholic fatty liver disease: The diagnosis and management. World Journal of Hepatology, 7(6): 846-846
Berstad, P., Konstantinova, S.V., Refsum, H., Nurk, E., Vollset, S.E., Tell, G.S., Ueland, P.M., Drevon, C.A., Ursin, G. (2007) Dietary fat and plasma total homocysteine concentrations in 2 adult age groups: The Hordaland Homocysteine Study. American Journal of Clinical Nutrition, 85(6): 1598-1605
Catena, C., Colussi, G., Nait, F., Capobianco, F., Sechi, L.A. (2015) Elevated Homocysteine Levels Are Associated with the Metabolic Syndrome and Cardiovascular Events in Hypertensive Patients. American Journal of Hypertension, 28(7): 943-950
Ciba, I., Widhalm, K. (2007) The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. Acta Paediatrica, 96(1): 109-112
Čolak, E., Pap, D., Majkić-Singh, N., Obradović, I. (2013) The association of obesity and liver enzyme activities in a student population at increased risk for cardiovascular disease. Journal of Medical Biochemistry, vol. 32, br. 1, str. 26-31
de Carvalho, S.C.R., Muniz, M.T.C., Siqueira, M.D.V., Siqueira, E.R.F., Gomes, A.V., Silva, K.A., Bezerra, L.C.L., D'almeida, V., de Oliveira, C.P.M.S. (2013) Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD). Nutrition Journal, 12(1): 37-37
Dimitrijević-Srećković, V. (2011) Metabolic sindrome in children and adolescents. u: Nedeljković S. [ur.] Yugoslav study of atherosclerosis precursors in school children: 20 years of follow-up, Belgrade: University of Belgrade-Faculty of Medicine, p. 731-45. (Serbian)
Dimitrijević-Srećković, V. (2011) Mediterranean cardioprotective nutrition. u: Nedeljković S. [ur.] Yugoslav study of atherosclerosis precursors in school children: 20 years of follow-up, Belgrade: University of Belgrade-Faculty of Medicine
Dimitrijević-Srećković, V. (2013) Metabolic syndrome, prediabetes and non alcoholic fatty liver diseases-treatment by Mediterranean diet. u: Dimitrijević-Srećković V., Vukašinović V. [ur.] FASTING: A WAY to LIFE: Christian fasting as a method for preventing and treating diabetes, atherosclerosis and cancer, Vrnjci: Interklima-grafika, p. 37-49
Faeh, D., Chiolero, A., Paccaud, F. (2006) Homocysteine as a risk factor for cardiovascular disease: 'Should we (still) worry about?. Swiss Med Wkly, 136(47-48): 745-56
Fonseca, V., Dicker-Brown, A., Ranganathan, S., Song, W., Barnard, J.R., Fink, L., Kern, P.A. (2000) Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism, 49(6): 736-741
Gami, A.S., Witt, B.J., Howard, D.E., Erwin, P.J., Gami, L.A., Somers, V.K., Montori, V.M. (2007) Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. Journal of the American College of Cardiology, 49(4): 403-14
García-Tevijano, E.R., Berasain, C., Rodríguez, J.A., Corrales, F.J., Arias, R., Martín-Duce, A., Caballería, J., Mato, J.M., Avila, M.A. (2001) Hyperhomocysteinemia in liver cirrhosis: Mechanisms and role in vascular and hepatic fibrosis. Hypertension, 38(5): 1217-21
Garcin, J.M., Cremades, S., Garcia-Hejl, C., Bordier, L., Dupuy, O., Mayaudon, H., Bauduceau, B. (2006) Is Hyperhomocysteinemia an Additional Risk Factor of the Metabolic Syndrome?. Metabolic Syndrome and Related Disorders, 4(3): 185-195
Gowdaiah, P.K., Nirgude, D., Hosamani, P.B. (2016) High sensitivity C-reactive protein in metabolic syndrome. International Journal of Advances in Medicine, 3(3): 607-610
Grundy, S.M., Brewer, B.H.Jr., Cleeman, J.I., Smith, S.C.Jr., Lenfant, C., American Heart Association, National Heart, Lung and Blood Institute (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109(3): 433-8
Han, L., Liu, Y., Wang, C., Tang, L., Feng, X., Astell-Burt, T., Wen, Q., Duan, D., Lu, N., Xu, G., Wang, K., Zhang, L., Gu, K., Chen, S., Ma, J., Zhang, T., You, D., Duan, S. (2017) Determinants of hyperhomocysteinemia in healthy and hypertensive subjects: A population-based study and systematic review. Clinical Nutrition, 36(5): 1215-1230
Jager, A., Kostense, P.J., Nijpels, G., Dekker, J.M., Heine, R.J., Bouter, L.M., Donker, A.J.M., Stehouwer, C.D.A. (2001) Serum homocysteine levels are associated with the development of (micro)albuminuria: The Hoorn study. Arteriosclerosis, Thrombosis, and Vascular Biology, 21(1): 74-81
Kumar, A., Palfrey, H.A., Pathak, R., Kadowitz, P.J., Gettys, T.W., Murthy, S.N. (2017) The metabolism and significance of homocysteine in nutrition and health. Nutrition & Metabolism, 14(1): 78-78
Li, Y., Jiang, C., Xu, G., Wang, N., Zhu, Y., Tang, C., Wang, X. (2008) Homocysteine Upregulates Resistin Production from Adipocytes in Vivo and in Vitro. Diabetes, 57(4): 817-827
Mauras, N., Delgiorno, C., Kollman, C., Bird, K., Morgan, M., Sweeten, S., Balagopal, P., Damaso, L. (2010) Obesity without Established Comorbidities of the Metabolic Syndrome Is Associated with a Proinflammatory and Prothrombotic State, Even before the Onset of Puberty in Children. Journal of Clinical Endocrinology & Metabolism, 95(3): 1060-1068
Mccully, K.S. (1969) Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol, 56(1): 111-28
Oron-Herman, M., Rosenthal, T., Sela, B.A. (2003) Hyperhomocysteinemia as a component of syndrome X. Metabolism, 52(11): 1491-1495
Pacana, T., Cazanave, S., Verdianelli, A., Patel, V., Min, H.K., Mirshahi, F., Quinlivan, E., Sanyal, A.J. (2015) Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. PLoS One, 10(8): e0136822-e0136822
Papatheodorou, L., Weiss, N. (2007) Vascular Oxidant Stress and Inflammation in Hyperhomocysteinemia. Antioxidants & Redox Signaling, 9(11): 1941-1958
Sheu, W.H., Lee, W.J., Chen, Y.T. (2000) Plasma homocysteine concentrations and insulin sensitivity in hypertensive subjects. American Journal of Hypertension, 13(1): 14-20
Soldatović, I., Vuković, R., Ćulafić, Đ., Gajić, M., Dimitrijević-Srećković, V. (2016) siMS Score: Simple Method for Quantifying Metabolic Syndrome. PLoS One, 11(1): e0146143-e0146143
Srećković, B. (2010) Determination of homocysteine level as an independent risk factor for coronary heart disease. Belgrade: University of Belgrade-Faculty of Medicine, [subspeciality thesis]. (Serbian)
Srećković, B., Srećkovic-Dimitrijević, V., Soldatović, I., Čolak, E., Šumarac-Dumanović, M., Janeski, H., Janeski, N., Gačić, J., Mrdović, I. (2017) Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 11(3): 179-182
Srećković, B., Soldatović, I., Čolak, E., Mrdović, I., Šumarac-Dumanović, M., Janeski, H., Janeski, N., Gačić, J., Dimitrijević-Srećković, V. (2018) Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score. Drug Metabolism and Personalized Therapy, 33(2): 99-103
Tawakol, A., Omland, T., Gerhard, M., Wu, J.T., Creager, M.A. (1997) Hyperhomocyst(e)inemia Is Associated with Impaired Endothelium-Dependent Vasodilation in Humans. Circulation, 95(5): 1119-1121
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2298/VSP180626132S
objavljen u SCIndeksu: 13.09.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0